People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Medicare no longer covers Wegovy specifically for weight loss purposes, though coverage may still be available when ...

compared to about 16% of those taking Wegovy, the study found. Weight loss was about 6% lower in men than in women in both groups, the authors noted. As participants in both groups lost more ...

compared to about 16% of those taking Wegovy, the AP reported, citing the study. Researchers explained in the study that weight loss was about 6% lower in men than in women in both groups ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women. These findings were presented at the European Congress on Obesity in Malaga ...

compared to about 16% of those taking Wegovy, the study found. Weight loss was about 6% lower in men than in women in both groups, the authors noted. As participants in both groups lost more ...